Erythropoiesis News and Research

RSS

Data from multiple clinical and preclinical studies evaluating Hematide announced

Affymax, Inc. and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients.

31 Oct 2009

Affymax to make multiple presentations on preclinical and clinical data of Hematide

Affymax, Inc. today announced multiple presentations at the American Society of Nephrology (ASN) Renal Week 2009 taking place October 27 through November 1 in San Diego.

23 Oct 2009

EPO and growth factor therapy safe for anemic MDS patients

Myelodysplastic syndromes (MDS), a group of blood disorders that can lead to acute myeloid leukemia (AML) in some patients, often cause severe anemia (when the body lacks a sufficient number of functional red blood cells).

18 Sep 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

Change to Medicare reimbursement policy may pose risks to black kidney patients

A change in Medicare reimbursement policy could make it more difficult for African Americans with kidney disease to access dialysis services, suggests a study in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

23 Apr 2009

Blood transfusions increase clot risk in hospitalized cancer patients

Blood transfusions used to treat anemia in patients with cancer are associated with an increased risk of life-threatening blood clots, at a similar rate as other treatments for cancer-induced anemia, according to scientists at the University of Rochester Medical Center.

24 Nov 2008

Takeda and Affymax provide update for Hematide in chemotherapy-induced anemia

Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.

28 Aug 2008

Avoiding spleen removal for Cooley's anemia sufferers

Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in one of the world's most common blood disorders, beta-thalassemia, commonly known as Cooley's anemia. Along with sickle-cell anemia, Cooley's anemia is the most commonly inherited disease in the world, affecting many people of Mediterranean descent, and 20 out of every 100,000 African-Americans. The World Health Organization estimates that between 50,000-100,000 children are born with the disease each year.

27 May 2008

Drug for anemic cancer patients raises risk of death

Millions of cancer patients take drugs to boost their red blood cells and health when they become anemic after chemotherapy.

27 Feb 2008

Anemia drug linked to blood clots, death in cancer patients

Treating anemia with a class of drugs known as erythropoiesis-stimulating agents (ESAs) is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs) and death among patients with cancer, according to an article in the February 27 issue of JAMA: The Journal of the American Medical Association.

27 Feb 2008

FDA reviews new data on risks of erythropoiesis-stimulating agents

The U.S. Food and Drug Administration (FDA) is reviewing new data from two studies that provide further evidence of the risks of anemia drugs known as erythropoiesis-stimulating agents, or ESAs.

4 Jan 2008

Anemia drugs linked with leukemic transformation in patients with primary myelofibrosis

Mayo Clinic researchers have reported the discovery of a link between erythropoiesis-stimulating agents (ESAs) and leukemic transformation (conversion to leukemia) of the blood disorder myelofibrosis.

10 Dec 2007

FDA strengthens warnings for erythropoiesis-stimulating agents

The U.S. Food and Drug Administration has approved revised boxed warnings and other safety-related product labeling changes for erythropoiesis-stimulating agents (ESAs), which treat certain types of anemia.

13 Nov 2007

Functional data analysis in renal anemia

Anemia is one of the most frequent complications of hemodialysis, and its correction is an important factor in restoring a tolerable quality of life to dialysis-dependent patients.

12 Jul 2007

Ago2 and hematopoiesis

Argonaute 2 (Ago2) is unique among its family: It is the only one of the four mammalian Argonaute proteins that exhibits endonuclease 'slicer' activity (facilitation of miRNA-guided cleavage of target mRNA).

12 Jul 2007

Caution against over-aggressive use of erythropoiesis-stimulating agents for cancer-related anemia

Echoing recent FDA warnings, a research group from Northern Ireland cautions against over-aggressive use of a group of drugs called "erythropoiesis-stimulating agents" (ESAs) to treat anemia in some cancer patients, according to a commentary in the April issue of The Oncologist, published by AlphaMed Press.

1 May 2007

Anemia treatment for patients with kidney disease can differ by dialysis facility type

Large, for-profit dialysis facilities appear to administer higher than necessary amounts of a medication for treating anemia in patients with kidney disease, compared to nonprofit facilities, according to a study in the April 18 issue of JAMA.

18 Apr 2007

FDA strengthens safety information for Erythropoiesis-Stimulating Agents (ESAs)

The U.S. Food and Drug Administration (FDA) has issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs), widely-used drugs for the treatment of anemia.

11 Mar 2007

Mechanism driving iron overload in thalassemia identified

Led by researchers at Weill Cornell Medical College in New York City, an international group of scientists has pinpointed a specific genetic relationship as the cause of dangerous iron overload in persons with a form of the inherited blood disease, beta-thalassemia.

14 Feb 2007

Affymax and Takeda announce agreement for commercialization of Hematide for anemia

Affymax and Takeda Pharmaceutical Company have announced that the companies have entered into an exclusive global agreement to develop and commercialize Affymax's lead product candidate, Hematide, for the treatment of anemia.

27 Jun 2006